Robert G. Strickley

5.2k total citations · 1 hit paper
22 papers, 2.1k citations indexed

About

Robert G. Strickley is a scholar working on Molecular Biology, Pediatrics, Perinatology and Child Health and Pharmaceutical Science. According to data from OpenAlex, Robert G. Strickley has authored 22 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Pediatrics, Perinatology and Child Health and 7 papers in Pharmaceutical Science. Recurrent topics in Robert G. Strickley's work include Drug Solubulity and Delivery Systems (7 papers), Pharmaceutical studies and practices (6 papers) and Protein purification and stability (5 papers). Robert G. Strickley is often cited by papers focused on Drug Solubulity and Delivery Systems (7 papers), Pharmaceutical studies and practices (6 papers) and Protein purification and stability (5 papers). Robert G. Strickley collaborates with scholars based in United States, Poland and Switzerland. Robert G. Strickley's co-authors include William J. Lambert, Leo Gu, Bradley D. Anderson, Sylvia Wu, Kirsten M. Stray, Bernard P. Murray, Christian Callebaut, Allen Y. Hong, Manoj C. Desai and Lianhong Xu and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, International Journal of Pharmaceutics and Pharmaceutical Research.

In The Last Decade

Robert G. Strickley

21 papers receiving 2.0k citations

Hit Papers

Solubilizing Excipients in Oral and Injectable Formulations 2004 2026 2011 2018 2004 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Solubilizing Excipients in Oral and Injectable Formulations
    2004 1.1k citations Robert G. Strickley Pharmaceutical Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert G. Strickley United States 16 780 571 347 286 283 22 2.1k
Mehran Yazdanian United States 20 582 0.7× 572 1.0× 278 0.8× 255 0.9× 291 1.0× 32 2.1k
Chandrasekharan Ramachandran United States 26 1.7k 2.2× 607 1.1× 444 1.3× 326 1.1× 289 1.0× 39 2.9k
Salomon Stavchansky United States 21 651 0.8× 511 0.9× 245 0.7× 272 1.0× 143 0.5× 58 2.1k
Isabel González‐Álvarez Spain 31 997 1.3× 732 1.3× 258 0.7× 213 0.7× 237 0.8× 143 3.2k
Nobuhito Shibata Japan 27 757 1.0× 411 0.7× 175 0.5× 149 0.5× 109 0.4× 96 2.2k
Sabine Kopp Switzerland 22 1.0k 1.3× 304 0.5× 420 1.2× 311 1.1× 121 0.4× 34 1.9k
Claus Larsen Denmark 32 991 1.3× 762 1.3× 259 0.7× 383 1.3× 412 1.5× 93 2.7k
Nicky Thomas Australia 32 997 1.3× 864 1.5× 423 1.2× 200 0.7× 300 1.1× 75 2.6k
William Couet France 36 746 1.0× 843 1.5× 212 0.6× 97 0.3× 205 0.7× 174 4.7k
David Fleisher United States 26 1.1k 1.4× 494 0.9× 198 0.6× 306 1.1× 143 0.5× 59 3.1k

Countries citing papers authored by Robert G. Strickley

Since Specialization
Citations

This map shows the geographic impact of Robert G. Strickley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert G. Strickley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert G. Strickley more than expected).

Fields of papers citing papers by Robert G. Strickley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert G. Strickley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert G. Strickley. The network helps show where Robert G. Strickley may publish in the future.

Co-authorship network of co-authors of Robert G. Strickley

This figure shows the co-authorship network connecting the top 25 collaborators of Robert G. Strickley. A scholar is included among the top collaborators of Robert G. Strickley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert G. Strickley. Robert G. Strickley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Litalien, Catherine, et al.. (2022). From paediatric formulations development to access: Advances made and remaining challenges. British Journal of Clinical Pharmacology. 88(10). 4349–4383. 14 indexed citations
2.
Strickley, Robert G. & William J. Lambert. (2021). A review of Formulations of Commercially Available Antibodies. Journal of Pharmaceutical Sciences. 110(7). 2590–2608.e56. 180 indexed citations
3.
Jordan, Robert, Matt X. G. Shao, Richard L. Mackman, et al.. (2015). Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection. Antimicrobial Agents and Chemotherapy. 59(8). 4889–4900. 27 indexed citations
4.
Xu, Lianhong, Allen Y. Hong, Bernard P. Murray, et al.. (2013). Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350). Bioorganic & Medicinal Chemistry Letters. 24(3). 995–999. 22 indexed citations
5.
Xu, Lianhong, Hongtao Liu, Bernard P. Murray, et al.. (2010). Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer. ACS Medicinal Chemistry Letters. 1(5). 209–213. 152 indexed citations
6.
Strickley, Robert G., et al.. (2007). Pediatric Drugs-A Review of Commercially Available Oral Formulations. Journal of Pharmaceutical Sciences. 97(5). 1731–1774. 127 indexed citations
7.
Strickley, Robert G.. (2004). Solubilizing Excipients in Oral and Injectable Formulations. Pharmaceutical Research. 21(2). 201–230. 1112 indexed citations breakdown →
8.
Strickley, Robert G.. (2000). Parenteral formulations of small molecules therapeutics marketed in the United States (1999)--Part I.. PubMed. 53(2). 152–49. 22 indexed citations
9.
Strickley, Robert G. & Bradley D. Anderson. (1997). Solid-state Stability of Human Insulin II. Effect of Water on Reactive Intermediate Partitioning in Lyophiles from pH 2–5 Solutions: Stabilization Against Covalent Dimer Formation. Journal of Pharmaceutical Sciences. 86(6). 645–653. 63 indexed citations
10.
Strickley, Robert G., et al.. (1996). Solid-State Stability of Human Insulin I. Mechanism and the Effect of Water on the Kinetics of Degradation in Lyophiles from pH 2–5 Solutions. Pharmaceutical Research. 13(8). 1142–1153. 51 indexed citations
11.
Strickley, Robert G. & Bradley D. Anderson. (1993). Solubilization and Stabilization of an Anti-HIV Thiocarbamate, NSC 629243, for Parenteral Delivery, Using Extemporaneous Emulsions. Pharmaceutical Research. 10(7). 1076–1082. 20 indexed citations
12.
Brandl, Michael, et al.. (1993). Degradation of 4′-azidothymidine in aqueous solution. International Journal of Pharmaceutics. 93(1-3). 75–83. 8 indexed citations
13.
14.
15.
Gu, Leo & Robert G. Strickley. (1990). A profound solvent effect on the diketopiperazine formation of the new dipeptide angiotensin-converting enzyme inhibitor, Moexipril. International Journal of Pharmaceutics. 60(2). 99–107. 11 indexed citations
16.
Strickley, Robert G., et al.. (1989). An Unexpected pH Effect on the Stability of Moexipril Lyophilized Powder. Pharmaceutical Research. 6(11). 971–975. 27 indexed citations
17.
Gu, Leo & Robert G. Strickley. (1988). Preformulation Stability Studies of the New Dipeptide Angiotensin-Converting Enzyme Inhibitor RS-10029. Pharmaceutical Research. 5(12). 765–771. 13 indexed citations
18.
19.
Gu, Leo & Robert G. Strickley. (1987). Diketopiperazine Formation, Hydrolysis, and Epimerization of the New Dipeptide Angiotensin-Converting Enzyme Inhibitor RS-10085. Pharmaceutical Research. 4(5). 392–397. 36 indexed citations
20.
Visor, Gary C., et al.. (1987). Parenteral formulation development for the positive inotropic agent RS-82856: solubility and stability enhancement through complexation and lyophilization.. PubMed. 41(4). 120–5. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mehran Yazdanian Breakdown of academic impact, for papers by Chandrasekharan Ramachandran Breakdown of academic impact, for papers by Salomon Stavchansky Breakdown of academic impact, for papers by Isabel González‐Álvarez Breakdown of academic impact, for papers by Nobuhito Shibata Breakdown of academic impact, for papers by Sabine Kopp Breakdown of academic impact, for papers by Claus Larsen Breakdown of academic impact, for papers by Nicky Thomas Breakdown of academic impact, for papers by William Couet Breakdown of academic impact, for papers by David Fleisher
Rankless by CCL
2026